Aktis Oncology, Inc.
AKTSFigures shown here come from public SEC filings. Dates beside each section show the available history.
SEC filings supply these figures; updates after the dates shown are not included. No annual financial history is available for this company. The latest insider filing shown is dated Apr 16, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Aktis Oncology, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-01-12 · NODELMAN OLEG: Larger than all 8 other insider purchases of Common Stock on file. SEC filing
Independent insiders buying near the same time
- 2026-01-12–2026-01-12: 9 event(s) across 6 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing , filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-01-12 | Kim Helen Susan · Director, 10% owner | Common Stock | P — Open market or private purchase | +22,545 | 18.00 | SEC filing |
| 2026-01-12 | NODELMAN OLEG · Director | Common Stock | P — Open market or private purchase | +144,443 | 18.00 | SEC filing |
| 2026-01-12 | Foley Todd · Director, 10% owner | Common Stock | P — Open market or private purchase | +232,870 | 18.00 | SEC filing |
| 2026-01-12 | EVNIN LUKE · 10% owner | Common Stock | P — Open market or private purchase | +1,112,777 | 18.00 | SEC filing |
| 2026-01-12 | Vida Ventures II, LLC · 10% owner | Common Stock | P — Open market or private purchase | +812,455 | 18.00 | SEC filing |
| 2026-01-12 | GADICKE ANSBERT · 10% owner | Common Stock | P — Open market or private purchase | +1,112,777 | 18.00 | SEC filing |
| 2026-01-12 | Kim Helen Susan · Director, 10% owner | Common Stock | P — Open market or private purchase | +812,455 | 18.00 | SEC filing |
| 2026-01-12 | NODELMAN OLEG · Director | Common Stock | P — Open market or private purchase | +2,077,779 | 18.00 | SEC filing |
Showing 8 of 9 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-04-15 | Gormley Glenn · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +37,866 | SEC filing |
| 2026-01-12 | GADICKE ANSBERT · 10% owner | Common Stock | C — Conversion of derivative security | +1,577,119 | SEC filing |
| 2026-01-12 | EVNIN LUKE · 10% owner | Series B Redeemable Convertible Preferred Stock | C — Conversion of derivative security | −6,000,000 | SEC filing |
| 2026-01-12 | Kim Helen Susan · Director, 10% owner | Series A Redeemable Convertible Preferred Stock | C — Conversion of derivative security | −14,838,250 | SEC filing |
| 2026-01-12 | Segal Lloyd Mitchell · Director | Common Stock | C — Conversion of derivative security | +19,631 | SEC filing |
| 2026-01-12 | Foley Todd · Director, 10% owner | Series Seed Redeemable Convertible Preferred Stock | C — Conversion of derivative security | −2,272,727 | SEC filing |
| 2026-01-12 | NODELMAN OLEG · Director | Common Stock | C — Conversion of derivative security | +2,270,879 | SEC filing |
| 2026-01-12 | Vida Ventures II, LLC · 10% owner | Series A Redeemable Convertible Preferred Stock | C — Conversion of derivative security | −411,750 | SEC filing |
Showing 8 of 11 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.